Entera Bio (ENTX)

Entera Bio on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).

Download CSV

5.5M

Short interest

settlement 2026-10-15

7.2

Days to cover

+2.0 days vs prior

63.1%

Short share of volume

2026-11-02

17,878

Fails to deliver

settlement 2026-10-14

Fri 13 Nov

Next earnings

estimated date

Insider flow, 90 days

0 buys, 0 sells

As of 2026-11-02.

Short interest

FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSON

As of 15 October 2026, short interest in ENTX is 5,548,769 shares, up 4,266,951 shares over the last month. Over the last 48 readings it ranged from 36,427 shares (29 August 2025) to 5,548,769 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 773K shares a day that is 7.2 days to cover.

Embed this chart.The embed keeps its attribution line.

<iframe src="https://xoomar.com/embed/stocks/entx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

Preview Dark previewAdd ?theme=dark to the src for a dark chart.

Settlement	Shares short	Change	Avg daily volume	Days to cover
2026-10-15	5,548,769	+130.8%	773,373	7.17
2026-09-30	2,403,597	+87.5%	464,319	5.18
2026-09-15	1,281,818	+44.7%	358,652	3.57
2026-08-31	885,945	-7.4%	358,374	2.47
2026-08-14	956,758	-16.8%	499,023	1.92
2026-07-31	1,150,114	+286.7%	7,664,901	1.00
2026-07-15	297,452	-10.6%	225,273	1.32
2026-06-30	332,658	+107.8%	5,613,473	1.00
2026-06-15	160,118	-9.9%	55,503	2.88
2026-05-29	177,670	-2.3%	75,921	2.34
2026-05-15	181,768	-5.5%	134,434	1.35
2026-04-30	192,284	-0.3%	279,110	1.00
2026-04-15	192,781	+10.0%	140,465	1.37
2026-03-31	175,306	+27.2%	205,953	1.00
2026-03-13	137,789	+10.9%	128,115	1.08
2026-02-27	124,213	+5.6%	73,018	1.70
2026-02-13	117,639	+14.9%	285,772	1.00
2026-01-30	102,393	+0.6%	136,573	1.00
2026-01-15	101,784	+2.8%	394,359	1.00
2025-12-31	99,052	-4.5%	181,513	1.00
2025-12-15	103,678	+0.6%	72,146	1.44
2025-11-28	103,037	-36.8%	83,036	1.24
2025-11-14	162,978	-17.1%	135,153	1.21
2025-10-31	196,467	+102.7%	324,483	1.00
2025-10-15	96,923	+86.9%	212,790	1.00
2025-09-30	51,864	+8.8%	46,777	1.11
2025-09-15	47,685	+30.9%	124,551	1.00
2025-08-29	36,427	-2.0%	33,316	1.09
2025-08-15	37,177	-33.0%	89,292	1.00
2025-07-31	55,477	+48.3%	415,139	1.00
2025-07-15	37,398	-32.4%	37,423	1.00
2025-06-30	55,283	-22.9%	34,173	1.62
2025-06-13	71,686	-9.5%	38,848	1.85
2025-05-30	79,198	+57.5%	44,478	1.78
2025-05-15	50,296	-64.2%	30,057	1.67
2025-04-30	140,530	+92.2%	57,240	2.46
2025-04-15	73,121	-2.2%	36,547	2.00
2025-03-31	74,749	-13.2%	38,416	1.95
2025-03-14	86,138	-13.7%	65,143	1.32
2025-02-28	99,787	-4.5%	46,920	2.13
2025-02-14	104,477	+59.6%	95,813	1.09
2025-01-31	65,475	-31.6%	82,764	1.00
2025-01-15	95,791	+102.4%	413,575	1.00
2024-12-31	47,328	-23.0%	49,376	1.00
2024-12-13	61,465	-2.4%	77,148	1.00
2024-11-29	62,957	+19.7%	28,849	2.18
2024-11-15	52,613	+19.2%	216,426	1.00
2024-10-31	44,153	+9.3%	19,410	2.27

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 2 November 2026, the short share of ENTX volume is 63.1%, down 5.0 points over the last five sessions. Over the last 30 readings it ranged from 21.1% (29 September 2026) to 94.5% (8 October 2026). The latest reading is 2.8 points below the 30-session average of 65.9%, on 141K shares reported.

Date	Short volume	Total volume	Short share	Exempt
2026-11-02	89K	141K	63.1%	0
2026-10-30	63K	151K	41.7%	0
2026-10-29	30K	52K	57.8%	0
2026-10-28	54K	80K	67.7%	108
2026-10-27	41K	90K	45.4%	0
2026-10-26	65K	95K	68.1%	0
2026-10-23	88K	152K	57.6%	0
2026-10-22	447K	488K	91.6%	0
2026-10-21	466K	532K	87.6%	0
2026-10-20	317K	456K	69.6%	125,435
2026-10-19	506K	604K	83.8%	252,346
2026-10-16	135K	253K	53.4%	44,733
2026-10-15	721K	879K	82.0%	152,901
2026-10-14	480K	547K	87.8%	5,000
2026-10-13	269K	432K	62.3%	355
2026-10-12	60K	112K	54.1%	12,080
2026-10-09	1.0M	1.1M	92.8%	75,247
2026-10-08	298K	316K	94.5%	0
2026-10-07	441K	478K	92.4%	13,895
2026-10-06	315K	391K	80.6%	539
2026-10-05	909K	976K	93.2%	17,040
2026-10-02	21K	30K	71.7%	700
2026-10-01	120K	231K	51.9%	17,958
2026-09-30	78K	330K	23.5%	35,957
2026-09-29	13K	62K	21.1%	0
2026-09-28	96K	198K	48.4%	780
2026-09-25	217K	491K	44.2%	900
2026-09-24	59K	99K	59.4%	0
2026-09-23	200K	378K	52.8%	300
2026-09-22	266K	344K	77.4%	2,735

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 14 October 2026, the fails-to-deliver balance in ENTX is 17,878 shares, down 115,536 shares over the last settlement date. Over the last 30 readings it ranged from 21 shares (7 October 2026) to 133,414 shares (13 October 2026).

Settlement	Shares failed	Price	Value
2026-10-14	17,878	$2.49	$45K
2026-10-13	133,414	$2.65	$354K
2026-10-07	21	$2.53	$53
2026-10-05	283	$2.86	$809
2026-09-28	11,078	$2.75	$30K
2026-09-25	8,776	$2.80	$25K
2026-09-24	7,640	$2.81	$21K
2026-09-22	1,495	$2.96	$4K
2026-09-18	57,027	$3.03	$173K
2026-09-17	3,582	$2.96	$11K
2026-09-16	66,476	$2.86	$190K
2026-09-15	4,559	$2.82	$13K
2026-09-11	31,725	$2.79	$89K
2026-09-10	10,359	$2.84	$29K
2026-09-09	3,035	$3.01	$9K
2026-09-08	10,086	$3.00	$30K
2026-09-04	3,209	$2.95	$9K
2026-09-03	552	$2.92	$2K
2026-09-02	69	$2.90	$200
2026-08-26	1,809	$3.47	$6K
2026-08-25	51	$3.42	$174
2026-08-24	10,124	$3.23	$33K
2026-08-21	861	$3.22	$3K
2026-08-19	7,276	$2.89	$21K
2026-08-17	10,196	$2.89	$29K
2026-08-14	1,000	$2.87	$3K
2026-08-13	5,527	$2.80	$15K
2026-08-12	548	$3.00	$2K
2026-08-10	3,760	$2.87	$11K
2026-08-07	8,124	$2.82	$23K

Insider trades

SEC Form 4, newest first. JSON

No open-market insider trades were reported for ENTX in the last 90 days. The most recent filings are listed below. Latest filing: Rubin Steven D (Director) on 2026-08-07.

Date	Insider	Title	Type	Shares	Price	Value	Owned after
2026-08-07	Rubin Steven D	Director	Grant	19K	$0.00	$0	34K
2026-08-07	Malca Yonatan	Director	Grant	23K	$0.00	$0	100K
2026-08-07	Taitel Haya	Director	Grant	21K	$0.00	$0	119K
2026-08-07	Germano Geno J	Director	Grant	25K	$0.00	$0	65K
2026-08-07	Ellis Sean	Director	Grant	20K	$0.00	$0	208K
2026-07-14	Toledano Miranda Jayne	Chief Executive Officer	Grant	73K	$0.00	$0	847K
2026-07-14	Toledano Miranda Jayne	Chief Executive Officer	Grant	348K	$0.00	$0	774K
2026-05-07	Galitzer Hillel	Chief Operating Officer	Grant	73K	$0.00	$0	164K
2026-05-07	Yaacov-Garbeli Dana	Chief Financial Officer	Grant	58K	$0.00	$0	171K
2026-05-07	Burshtein Gregory	Chief of R&D	Grant	88K	$0.00	$0	189K
2026-03-09	Germano Geno J	Director	Buy	20K	$1.30	$26K	40K
2026-03-05	Ellis Sean	Director	Buy	10K	$1.23	$12K	188K
2026-02-12	Rubin Steven D	Director	Buy	5K	$1.49	$7K	15K
2026-02-10	Taitel Haya	Director	Buy	8K	$1.48	$11K	n/a
2026-02-10	Germano Geno J	Director	Buy	20K	$1.49	$30K	n/a
2026-02-09	Rubin Steven D	Director	Buy	10K	$1.20	$12K	10K
2026-02-09	Ellis Sean	Director	Buy	18K	$1.24	$22K	178K
2026-01-01	OSTROV GERALD M	Director	Grant	29K	$0.00	$0	76K
2026-01-01	Malca Yonatan	Director	Grant	30K	$0.00	$0	77K
2026-01-01	LIEBERMAN GERALD M	Director	Grant	38K	$0.00	$0	338K
2026-01-01	Taitel Haya	Director	Grant	26K	$0.00	$0	91K
2026-01-01	Ellis Sean	Director	Grant	25K	$0.00	$0	160K
2025-12-29	Toledano Miranda Jayne	Chief Executive Officer	Buy	11K	$1.81	$20K	427K
2025-07-16	Toledano Miranda Jayne	Chief Executive Officer	Grant	44K	$0.00	$0	416K
2025-07-16	Toledano Miranda Jayne	Chief Executive Officer	Grant	137K	$0.00	$0	372K
2025-07-16	Yaacov-Garbeli Dana	Chief Financial Officer	Grant	26K	$0.00	$0	113K
2025-07-16	Burshtein Gregory	Chief of R&D	Grant	26K	$0.00	$0	101K
2025-04-28	Galitzer Hillel	Chief Operating Officer	Grant	26K	$0.00	$0	91K
2025-04-01	LIEBERMAN GERALD M	Director	Exercise or conversion	24K	$1.00	$24K	300K
2025-01-15	Ellis Sean	Director	Grant	7K	$0.00	$0	135K
2025-01-15	LIEBERMAN GERALD M	Director	Grant	11K	$0.00	$0	276K
2025-01-15	Malca Yonatan	Director	Grant	8K	$0.00	$0	47K
2025-01-15	OSTROV GERALD M	Director	Grant	8K	$0.00	$0	47K
2025-01-15	Taitel Haya	Director	Grant	7K	$0.00	$0	65K
2024-10-02	Ellis Sean	Director	Grant	7K	$0.00	$0	128K
2024-10-02	LIEBERMAN GERALD M	Director	Grant	11K	$0.00	$0	265K
2024-10-02	Malca Yonatan	Director	Grant	9K	$0.00	$0	39K
2024-10-02	OSTROV GERALD M	Director	Grant	8K	$0.00	$0	39K
2024-10-02	Taitel Haya	Director	Grant	7K	$0.00	$0	58K
2024-08-27	LIEBERMAN GERALD M	Director	Grant	27K	$0.00	$0	254K
2024-08-27	Malca Yonatan	Director	Grant	23K	$0.00	$0	30K
2024-08-27	Ellis Sean	Director	Grant	18K	$0.00	$0	120K
2024-08-27	Taitel Haya	Director	Grant	15K	$0.00	$0	50K
2024-08-27	OSTROV GERALD M	Director	Grant	20K	$0.00	$0	30K
2024-07-31	Toledano Miranda Jayne	Chief Executive Officer	Grant	124K	$0.00	$0	235K
2024-04-19	Galitzer Hillel	Chief Operating Officer	Grant	30K	$0.00	$0	64K
2024-04-19	Yaacov-Garbeli Dana	Chief Financial Officer	Grant	30K	$0.00	$0	87K
2024-01-12	Taitel Haya	Director	Buy	10K	$0.99	$9K	35K
2024-01-10	Taitel Haya	Director	Buy	8K	$0.77	$6K	26K
2023-12-22	Toledano Miranda Jayne	Chief Executive Officer	Buy	24K	$0.71	$17K	111K
2023-12-22	LIEBERMAN GERALD M	Director	Buy	24K	$0.71	$17K	227K
2023-08-22	Taitel Haya	Director	Buy	18K	$0.62	$11K	18K
2023-08-21	Ellis Sean	Director	Buy	40K	$0.60	$24K	102K
2023-08-21	LIEBERMAN GERALD M	Director	Buy	20K	$0.59	$12K	214K
2023-04-04	Toledano Miranda Jayne	Chief Executive Officer	Buy	30K	$1.01	$30K	87K
2022-11-14	LIEBERMAN GERALD M	Director	Buy	4K	$0.59	$2K	6K
2022-11-14	LIEBERMAN GERALD M	Director	Buy	4K	$0.56	$2K	6K
2022-11-14	LIEBERMAN GERALD M	Director	Buy	4K	$0.56	$2K	6K
2022-11-14	LIEBERMAN GERALD M	Director	Buy	34K	$0.57	$19K	194K
2022-11-14	LIEBERMAN GERALD M	Director	Buy	4K	$0.56	$2K	6K
2022-11-14	Yaacov-Garbeli Dana	Chief Financial Officer	Buy	27K	$0.54	$14K	57K
2022-11-11	Toledano Miranda Jayne	Chief Executive Officer	Buy	50K	$0.53	$27K	57K
2022-11-11	Ellis Sean	Director	Buy	30K	$0.53	$16K	62K
2022-11-11	Yaacov-Garbeli Dana	Chief Financial Officer	Buy	30K	$0.52	$16K	30K
2022-07-21	LIEBERMAN GERALD M	Director	Buy	19K	$1.68	$33K	160K
2022-07-21	Ellis Sean	Director	Buy	15K	$1.64	$24K	32K
2022-01-20	Schwartz Phillip	President of R&D	Buy	10K	$2.53	$25K	607K
2022-01-19	Ratan Ramesh	U.S.based CFO	Buy	10K	$2.44	$24K	10K
2022-01-18	LIEBERMAN GERALD M	Director	Buy	700	$2.81	$2K	2K
2022-01-18	LIEBERMAN GERALD M	Director	Buy	700	$2.78	$2K	2K
2022-01-18	LIEBERMAN GERALD M	Director	Buy	700	$2.81	$2K	2K
2022-01-18	Ellis Sean	Director	Buy	10K	$2.81	$28K	10K
2022-01-18	Mayron Ron	Director	Buy	7K	$2.80	$20K	7K
2022-01-18	LIEBERMAN GERALD M	Director	Buy	700	$2.78	$2K	2K
2022-01-18	JAMAS SPIROS	Chief Executive Officer	Buy	10K	$2.85	$29K	10K
2022-01-14	Toledano Miranda Jayne	Director	Buy	7K	$2.79	$19K	7K
2022-01-13	Malca Yonatan	Director	Buy	7K	$2.74	$20K	7K
2022-01-13	OSTROV GERALD M	Director	Buy	10K	$2.74	$27K	10K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

17 holders report 5% or more of ENTX in their latest filing, 6 on Schedule 13D (active intent). The largest reported stake is LAMPERT MARK N at 10.0% of the class (17,225,121 shares), filed 2026-08-04 for an event on 2026-07-28.

Filed	Form	Holder	Shares	Of class	Event
2026-10-30	13G	Venrock Healthcare Capital Partners III, L.P.partnership	8.9M	5.1%	2026-10-23
2026-10-30	13G	VHCP Co-Investment Holdings III, LLCother entity	8.9M	5.1%	2026-10-23
2026-10-30	13G	Venrock Healthcare Capital Partners EG, L.P.partnership	8.9M	5.1%	2026-10-23
2026-10-30	13G	VHCP Management III, LLCother entity	8.9M	5.1%	2026-10-23
2026-10-30	13G	VHCP Management EG, LLCother entity	8.9M	5.1%	2026-10-23
2026-10-30	13G	Nimish Shahindividual	8.9M	5.1%	2026-10-23
2026-10-30	13G	Bong Y. Kohindividual	8.9M	5.1%	2026-10-23
2026-08-04	13G	Vivo Opportunity, LLCother entity	11.8M	6.9%	2026-07-28
2026-08-04	13G	Vivo Opportunity Co-Invest (Cycle 3), L.P.partnership	4.8M	2.8%	2026-07-28
2026-08-04	13G	Vivo Opportunity Fund Holdings, L.P.partnership	4.3M	2.5%	2026-07-28
2026-08-04	13G	Vivo Opportunity Co-Invest, L.P.partnership	2.7M	1.6%	2026-07-28
2026-08-04	13G	Vivo Opportunity Cayman Fund, L.P.partnership	438K	0.3%	2026-07-28
2026-08-04	13G	Vivo Opportunity Cayman, LLCother entity	438K	0.3%	2026-07-28
2026-08-04	13G	Patrick G. Enrightindividual	7.8M	4.6%	2026-07-28
2026-08-04	13G	Longitude Capital Partners V, LLCother entity	7.8M	4.6%	2026-07-28
2026-08-04	13G	Longitude Venture Partners V, L.P.partnership	7.8M	4.6%	2026-07-28
2026-08-04	13G	Juliet Tammenoms Bakkerindividual	7.8M	4.6%	2026-07-28
2026-08-04	13G	TCG Crossover GP III, LLCother entity	12.3M	7.1%	2026-07-28
2026-08-04	13G	TCG Crossover Fund III, L.P.partnership	12.3M	7.1%	2026-07-28
2026-08-04	13G	Chen Yuindividual	12.3M	7.1%	2026-07-28
2026-08-04	13G	Brian Liuindividual	7.1M	4.1%	2026-07-28
2026-08-04	13G	Seven Fleet Capital Management LPother entity	7.1M	4.1%	2026-07-28
2026-08-04	13G	Seven Fleet Capital Management GP LLCother entity	7.1M	4.1%	2026-07-28
2026-08-04	13G	Seven Fleet Master Fund LPpartnership	5.1M	3.0%	2026-07-28
2026-08-04	13G	Seven Fleet Horizon Master Fund LPpartnership	2.0M	1.1%	2026-07-28
2026-08-04	13D	LAMPERT MARK Nindividual	17.2M	10.0%	2026-07-28
2026-08-04	13D	BVF PARTNERS L P/ILinvestment adviser, partnership	17.2M	10.0%	2026-07-28
2026-08-04	13D	BVF INC/ILcorporation	17.2M	10.0%	2026-07-28
2026-08-04	13D	BVF GP HOLDINGS LLCother entity	15.9M	9.2%	2026-07-28
2026-08-04	13D	BIOTECHNOLOGY VALUE FUND L Ppartnership	9.2M	5.3%	2026-07-28
2026-08-04	13D	BVF I GP LLCother entity	9.2M	5.3%	2026-07-28
2026-08-04	13D	BIOTECHNOLOGY VALUE FUND II LPpartnership	6.7M	3.9%	2026-07-28
2026-08-04	13D	BVF II GP LLCother entity	6.7M	3.9%	2026-07-28
2026-08-04	13D	BVF Partners OS Ltd.corporation	1.1M	0.7%	2026-07-28
2026-08-04	13D	Biotechnology Value Trading Fund OS LPpartnership	1.1M	0.7%	2026-07-28
2025-11-14	13G/Ano. 1	Point72 Asset Management, L.P.partnership	1.2M	2.6%	2025-09-30
2025-11-14	13G/Ano. 1	Point72 Capital Advisors, Inc.corporation	1.2M	2.6%	2025-09-30
2025-11-14	13G/Ano. 1	Steven A. Cohenindividual	1.2M	2.6%	2025-09-30

13F holders

Tracked managers holding ENTX at their latest 13F. JSON

2 of the 30 tracked managers held ENTX at their latest 13F, $722K in total at quarter-end prices. Renaissance Technologies is the largest at $653K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 0 added shares and 2 cut.

Fund	Quarter	Shares	Value	Of portfolio	Change in shares
Renaissance Technologies	2026-06-30	369K	$653K	0.00%	-105K
Citadel Advisors	2026-06-30	39K	$69K	0.00%	-207K

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

What this page is

Entera Bio in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows Entera Bio (ENTX), SEC CIK 1638097, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest: FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
Daily short volume: FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
Fails to deliver: SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
Large holders: SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-30.JSON and CSV
13F holders: SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Earnings dates: SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-07.JSON and CSV
Insider trades: SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-07.JSON and CSV
Company record: EDGAR filing index for CIK 1638097Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits: 10 requests a minute without a key, 30 with a free key from a free account.

How to read it

Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other companies the SEC classifies as biological products, (no diagnostic substances)

Other company pages

Datasets

Frequently Asked Questions

How much of ENTX is sold short?

5,548,769 shares were held short at the 2026-10-15 settlement, 7.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.

What is ENTX's daily short volume?

On 2026-11-02, 89,319 of the 141,461 ENTX shares reported to FINRA were sold short, 63.1% of the day's reported volume. Short volume is a flow for one day, not a position.

Does ENTX have fails to deliver?

The SEC's latest file shows 17,878 ENTX shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.

Are ENTX insiders buying or selling?

No open-market insider trades were reported for ENTX in the last 90 days. The most recent filings are listed below. Latest filing: Rubin Steven D (Director) on 2026-08-07.

Who owns 5% or more of ENTX?

Which tracked 13F managers own ENTX?

2 of the 30 tracked 13F managers held ENTX shares at their latest filing, $722K in all. The largest: Renaissance Technologies (369K shares, $653K), Ken Griffin's Citadel Advisors (39K shares, $69K).

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.